TearLab Reports on Launch of a New 1,000 Patient Multi-Center DED Prevalence Study in the UK
17 Décembre 2013 - 2:00PM
In collaboration with the United Kingdom's National Health Service
(NHS), four ophthalmologists are beginning a large 1,000 patient
multi-center study to assess the overall prevalence of Dry Eye
Disease ("DED").
Patients who suffer from a wide variety of eye complications
presenting daily in NHS clinics will be the primary target group of
this study. Tear osmolarity testing will be incorporated as a
diagnostic measure to detect the presence of DED. The study will be
conducted under ethical controls, adopted by the National Institute
of Health Research in the UK and will allow UK ophthalmologists to
view DED in their own patient base.
"This is a unique opportunity to truly assess the prevalence of
DED in a large patient population utilizing objective data, now
available to us through osmolarity testing," commented Miss
Francesca Harman, THH, a highly experienced NHS Consultant
Ophthalmologist from the London area who will be leading the
study.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets
lab-on-a-chip technologies that enable eye care practitioners to
improve standard of care by objectively and quantitatively testing
for disease markers in tears at the point-of-care. The
TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the
first assay developed for the award-winning TearLab Osmolarity
System. Headquartered in San Diego, CA, TearLab Corporation's
common shares trade on the NASDAQ Capital Market under the symbol
'TEAR' and on the Toronto Stock Exchange under the symbol
'TLB'.
Forward-Looking Statements
This press release may contain forward-looking
statements. These statements relate to future events and are
subject to risks, uncertainties and assumptions about TearLab.
Examples of forward-looking statements in this press release
include statements regarding the future potential of the TearLab
Osmolarity System and the related impact on our sales. These
statements are only predictions based on our current expectations
and projections about future events. You should not place
undue reliance on these statements. Actual events or results may
differ materially. Many factors may cause our actual results
to differ materially from any forward-looking statement, including
the factors detailed in our filings with the Securities and
Exchange Commission and Canadian securities regulatory authorities,
including but not limited to our annual and quarterly reports on
Forms 10-K and 10-Q. We do not undertake to update any
forward-looking statements.
CONTACT: Stephen Kilmer
(647) 872-4849
skilmer@tearlab.com
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Talbots (The) (New York Stock Exchange): 0 recent articles
Plus d'articles sur